

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the  
present  
NEWS 4 DEC 08 INPADOC: Legal Status data reloaded  
NEWS 5 SEP 29 DISSABS now available on STN  
NEWS 6 OCT 10 PCTFULL: Two new display fields added  
NEWS 7 OCT 21 BIOSIS file reloaded and enhanced  
NEWS 8 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced  
NEWS 9 NOV 24 MSDS-CCOHS file reloaded  
NEWS 10 DEC 08 CABA reloaded with left truncation  
NEWS 11 DEC 08 IMS file names changed  
NEWS 12 DEC 09 Experimental property data collected by CAS now available  
in REGISTRY  
NEWS 13 DEC 09 STN Entry Date available for display in REGISTRY and CA/CAPLUS  
NEWS 14 DEC 17 DGENE: Two new display fields added  
NEWS 15 DEC 18 BIOTECHNO no longer updated  
NEWS 16 DEC 19 CROPU no longer updated; subscriber discount no longer  
available  
NEWS 17 DEC 22 Additional INPI reactions and pre-1907 documents added to CAS  
databases  
NEWS 18 DEC 22 IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields  
NEWS 19 DEC 22 ABI-INFORM now available on STN  
NEWS 20 JAN 27 Source of Registration (SR) information in REGISTRY updated  
and searchable  
NEWS 21 JAN 27 A new search aid, the Company Name Thesaurus, available in  
CA/CAPLUS  
  
NEWS EXPRESS DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:28:33 ON 30 JAN 2004

=> file medline, uspatful, dgene, embase, wpids, fsta, biosis, COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 17:28:55 ON 30 JAN 2004

FILE 'USPATFULL' ENTERED AT 17:28:55 ON 30 JAN 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 17:28:55 ON 30 JAN 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 17:28:55 ON 30 JAN 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 17:28:55 ON 30 JAN 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 17:28:55 ON 30 JAN 2004  
COPYRIGHT (C) 2004 International Food Information Service

FILE 'BIOSIS' ENTERED AT 17:28:55 ON 30 JAN 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

=> s GLP-1  
5 FILES SEARCHED...  
L1 7447 GLP-1

=> s l1 and analog.  
L2 514 L1 AND ANALOG

=> s l2 and (7-34)  
L3 61 L2 AND (7-34)

=> s l3 and tonicity modifier  
L4 1 L3 AND TONICITY MODIFIER

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 1 USPATFULL on STN  
TI Peptide pharmaceutical formulations  
AB A pharmaceutical composition for administration to a mammal is disclosed. The composition includes a therapeutically effective amount of a peptide, such as a GLP-1 molecule, a PTH molecule, or a GRF molecule. The composition further includes a buffer including a weak acid having an acid dissociation constant value of greater than about 1.times.10.sup.-5, such as acetic acid. The composition also includes an excipient for making the composition generally isotonic, such as D-mannitol.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:119850 USPATFULL  
TITLE: Peptide pharmaceutical formulations  
INVENTOR(S): Holmquist, Barton, Lincoln, NE, UNITED STATES  
Dormady, Daniel C., Omaha, NE, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002061838	A1	20020523
APPLICATION INFO.:	US 2001-858880	A1	20010517 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205377P	20000517 (60)
	US 2000-205262P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Beth A. Burrous, FOLEY & LARDNER, Suite 500, 3000 K Street, N.W., Washington, DC, 20007-5109	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	929	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=> d his

(FILE 'HOME' ENTERED AT 17:28:33 ON 30 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT 17:28:55 ON 30 JAN 2004

L1 7447 S GLP-1  
 L2 514 S L1 AND ANALOG  
 L3 61 S L2 AND (7-34)  
 L4 1 S L3 AND TONICITY MODIFIER

=> s l3 and solution  
 L5 61 L3 AND SOLUTION

=> s l5 and (7-35)  
 L6 52 L5 AND (7-35)

=> s l6 and (7-37)  
 L7 48 L6 AND (7-37)

=> s l7 and (7-36)  
 L8 48 L7 AND (7-36)

=> s l8 and pH  
 L9 48 L8 AND PH

=> s l8 and basic pH  
 L10 4 L8 AND BASIC PH

=> d l10 ti abs ibib tot

L10 ANSWER 1 OF 4 USPATFULL on STN  
 TI Indole carboxylic acids as thyroid receptor ligands  
 AB A compound of the formula ##STR1##

wherein W, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.13 are as defined herein, useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:113548 USPATFULL  
 TITLE: Indole carboxylic acids as thyroid receptor ligands  
 INVENTOR(S): Aspnes, Gary E., Rockville, RI, UNITED STATES  
 Chiang, Yuan-Ching P., East Lyme, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003078289	A1	20030424
APPLICATION INFO.:	US 2002-255180	A1	20020924 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-325385P	20010926 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3688	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 4 USPATFULL on STN

TI Process for solubilizing glucagon-like peptide 1 compounds  
 AB Disclosed is a method of preparing a GLP-1 compound that is soluble in aqueous solution at pH 7.4 from a GLP-1 compound that is substantially insoluble in aqueous solution at pH 7.4. The insoluble GLP-1 compound is dissolved in aqueous base or in aqueous acid to form a GLP-1 solution. The GLP-1 solution is then neutralized to a pH at which substantially no amino acid racemization of the GLP-1 compounds occurs, after which the soluble GLP-1 compound is isolated from the neutralized solution.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:86804 USPATFULL  
 TITLE: Process for solubilizing glucagon-like peptide 1 compounds  
 INVENTOR(S): Prouty, Walter Francis, JR., Indianapolis, IN, UNITED STATES  
 Rinella, Joseph Vincent, JR., Ypsilanti, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003060412	A1	20030327
APPLICATION INFO.:	US 2002-169657	A1	20020628 (10)
	WO 2001-US10		20010116
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	1103		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 4 USPATFULL on STN

TI Glucagon-like peptide-1 crystals  
 AB The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating diabetes, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:65340 USPATFULL  
TITLE: Glucagon-like peptide-1 crystals  
INVENTOR(S): Hermeling, Ronald Norbert, Indianapolis, IN, UNITED STATES  
Hoffmann, James Arthur, Greenwood, IN, UNITED STATES  
Narasimhan, Chakravarthy, Carmel, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003045464	A1	20030306
	US 6555521	B2	20030429
APPLICATION INFO.:	US 2001-997792	A1	20011130 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-209799, filed on 11 Dec 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69728P	19971216 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, LILLY CORPORATE CENTER, DROP CODE 1104, INDIANAPOLIS, IN, 46285	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1128	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L10 ANSWER 4 OF 4 USPATFULL on STN  
TI GLUCAGON-LIKE PEPTIDE-1 CRYSTALS  
AB The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating diabetes, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:134217 USPATFULL  
TITLE: GLUCAGON-LIKE PEPTIDE-1 CRYSTALS  
INVENTOR(S): HERMELING, RONALD NORBERT, INDIANAPOLIS, IN, United States  
HOFFMANN, JAMES ARTHUR, GREENWOOD, IN, United States  
NARASIMHAN, CHAKAVARTHY, CARMEL, IN, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001014666	A1	20010816
	US 6380357	B2	20020430
APPLICATION INFO.:	US 1998-209799	A1	19981211 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ROBERT A CONRAD, ELI LILLY AND COMPANY, PATENT DIVISION/RSM, LILLY CORPORATE CENTER, INDIANAPOLIS, IN, 46285		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1106		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

=> d his

(FILE 'HOME' ENTERED AT 17:28:33 ON 30 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT

17:28:55 ON 30 JAN 2004

L1 7447 S GLP-1  
L2 514 S L1 AND ANALOG  
L3 61 S L2 AND (7-34)  
L4 1 S L3 AND TONICITY MODIFIER  
L5 61 S L3 AND SOLUTION  
L6 52 S L5 AND (7-35)  
L7 48 S L6 AND (7-37)  
L8 48 S L7 AND (7-36)  
L9 48 S L8 AND PH  
L10 4 S L8 AND BASIC PH

=> s l9 and preservative

L11 12 L9 AND PRESERVATIVE

=> d l11 ti abs ibib tot

L11 ANSWER 1 OF 12 USPATFULL on STN

TI Inhibition of beta cell degeneration

AB This invention relates to a method for modulating, inhibiting or decreasing or preventing beta cell degeneration, loss of beta cell function, beta cell dysfunction, and/or death of beta cells, such as necrosis or apoptosis of beta cells in a subject comprising administering a GLP-1 agonist to said subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312646 USPATFULL

TITLE: Inhibition of beta cell degeneration

INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, DENMARK  
Godtfredsen, Carsten Foged, Herlev, DENMARK  
Petersen, Jacob Sten, Copenhagen O, DENMARK  
Carr, Richard David, Vaerloese, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003220251	A1	20031127
APPLICATION INFO.:	US 2003-372485	A1	20030224 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-709856, filed on 10 Nov 2000, GRANTED, Pat. No. US 6569832		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1999-1628	19991112
	DK 2000-270	20000222
	US 1999-166800P	19991122 (60)
	US 2000-185845P	20000229 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Reza Green, Esq., Novo Nordisk Pharmaceuticals, Inc., 100 College Road West, Princeton, NJ, 08540	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2373	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 12 USPATFULL on STN

TI Derivatives of GLP-1 analogs

AB The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:283328 USPATFULL

TITLE: Derivatives of GLP-1 analogs

INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, DENMARK

Huusfeldt, Per Olaf, Kobenhavn K, DENMARK  
 Nielsen, Per Franklin, Vaerloose, DENMARK  
 Kaarsholm, Niels C., Vanlose, DENMARK  
 Olsen, Helle Birk, Allerod, DENMARK  
 Bjorn, Soren Erik, Lyngby, DENMARK  
 Pedersen, Freddy Zimmerdahl, Vaerloose, DENMARK  
 Madsen, Kjeld, Vaerloose, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199672	A1	20031023
APPLICATION INFO.:	US 2002-285079	A1	20020819 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-398111, filed on 16 Sep 1999, GRANTED, Pat. No. US 6458924		
	Continuation-in-part of Ser. No. US 1999-265141, filed on 8 Mar 1999, GRANTED, Pat. No. US 6384016		
	Continuation-in-part of Ser. No. US 1999-258750, filed on 26 Feb 1999, GRANTED, Pat. No. US 6268343		
	Continuation-in-part of Ser. No. US 1998-38432, filed on 11 Mar 1998, ABANDONED		
	Continuation-in-part of Ser. No. US 1997-918810, filed on 26 Aug 1997, ABANDONED		
	Continuation-in-part of Ser. No. WO 1997-DK340, filed on 22 Aug 1997, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1996-931	19960830
	DK 1996-1259	19961108
	DK 1996-1470	19961220
	DK 1998-263	19980227
	DK 1998-264	19980227
	DK 1998-268	19980227
	EP 1998-610006	19980313
	DK 1998-507	19980408
	DK 1998-272	19980227
	DK 1998-274	19980227
	DK 1998-508	19980408
	DK 1998-509	19980408
	US 1997-35904P	19970124 (60)
	US 1997-36226P	19970125 (60)
	US 1997-36255P	19970124 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6401

NUMBER OF CLAIMS: 238  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 1 Drawing Page(s)  
 LINE COUNT: 19138  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 12 USPATFULL on STN

TI Protein formulations  
 AB The present invention discloses a stable, soluble formulation comprising a medically useful peptide or protein, a hydrophobic **preservative**, and nicotinamide. Said storage-stable, soluble formulation is useful as a multi-use pharmaceutical product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:100072 USPATFULL  
 TITLE: Protein formulations  
 INVENTOR(S): Rinella, Vincent Joseph, JR., Brownsburg, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069182	A1	20030410
	US 6573237	B2	20030603
APPLICATION INFO.:	US 2002-170301	A1	20020612 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-787500, filed on 16 Mar 2001, GRANTED, Pat. No. US 6440930		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	700		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L11 ANSWER 4 OF 12 USPATFULL on STN  
 TI Glucagon-like peptide-1 crystals  
 AB The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating diabetes, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:65340 USPATFULL  
 TITLE: Glucagon-like peptide-1 crystals  
 INVENTOR(S): Hermeling, Ronald Norbert, Indianapolis, IN, UNITED STATES  
 Hoffmann, James Arthur, Greenwood, IN, UNITED STATES  
 Narasimhan, Chakravarthy, Carmel, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003045464	A1	20030306
	US 6555521	B2	20030429
APPLICATION INFO.:	US 2001-997792	A1	20011130 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-209799, filed on 11 Dec 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69728P	19971216 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, LILLY CORPORATE CENTER, DROP CODE 1104, INDIANAPOLIS, IN, 46285	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1128	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L11 ANSWER 5 OF 12 USPATFULL on STN  
 TI Use of glycogen phosphorylase inhibitors  
 AB The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.



The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:4123 USPATFULL  
TITLE: Use of glycogen phosphorylase inhibitors  
INVENTOR(S): Treadway, Judith L., Mystic, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003004162	A1	20030102
APPLICATION INFO.:	US 2001-813335	A1	20010320 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-191381P	20000322 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159,, Eastern Point Road, Groton, CT, 06340	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4011	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 12 USPATFULL on STN

TI GLP-1 formulations

AB Methods and formulations are presented that provide for a) the oral absorption of GLP-1 peptides that bind surfactants; and b) long-term storage of formulations containing these peptides. For example, a GLP-1/DSS complex is administered orally instead of parenterally, which is much more convenient for, and facilitates compliance with diabetic patients and persons with other GLP-1 treated conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:228306 USPATFULL  
TITLE: GLP-1 formulations  
INVENTOR(S): Hoffmann, James Arthur, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002123466	A1	20020905
APPLICATION INFO.:	US 2002-72540	A1	20020208 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-573809, filed on 18 May 2000, GRANTED, Pat. No. US 6410513 Continuation of Ser. No. WO 1998-US25515, filed on 2 Dec 1998, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-67600P	19971205 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	

LINE COUNT: 546  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 12 USPATFULL on STN

TI Protein formulations

AB The present invention discloses a stable, soluble formulation comprising a medically useful peptide or protein, a hydrophobic preservative, and nicotinamide. Said storage-stable, soluble formulation is useful as a multi-use pharmaceutical product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:217237 USPATFULL

TITLE: Protein formulations

INVENTOR(S): Rinella, Jr., Vincent Joseph, Brownsburg, IN, United States

PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6440930	B1	20020827
	WO 2000015224		20000323
APPLICATION INFO.:	US 2001-787500		20010316 (9)
	WO 1999-US21055		19990914
			20010316 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-100687P	19980917 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Henley, III, Raymond	
LEGAL REPRESENTATIVE:	Stewart, Mark J., Davis, Paula K.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	715	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 8 OF 12 USPATFULL on STN

TI Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders

AB The present invention relates to methods for prevention and treatment of bone-related or nutrition-related disorders using a GLP molecule or GLP activator either alone or in combination with another therapeutic. The present invention also encompasses methods of diagnosing or monitoring the progression of a disorder. The invention also encompasses methods of monitoring the effectiveness of treatment of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:67183 USPATFULL

TITLE: Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders

INVENTOR(S): Henriksen, Dennis Bang, Alleroed, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037836	A1	20020328
APPLICATION INFO.:	US 2001-954304	A1	20010918 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-22844	20000918

GB 2000-29920 20001207  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERI  
YORK, NY, 100362711  
NUMBER OF CLAIMS: 57  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 5 Drawing Page(s)  
LINE COUNT: 2814  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 12 USPATFULL on STN

TI GLP-1 formulations

AB Methods and formulations are presented that provide for a) the oral absorption of GLP-1 peptides that bind surfactants; and b) long-term storage of formulations containing these peptides. For example, a GLP-1/DSS complex is administered orally instead of parenterally, which is much more convenient for, and facilitates compliance with diabetic patients and persons with other GLP-1 treated conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:57761 USPATFULL  
TITLE: GLP-1 formulations  
INVENTOR(S): Hoffmann, James Arthur, Greenwood, IN, United States  
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6358924	B1	20020319
APPLICATION INFO.:	US <del>2000</del> -585181		20000601 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1998-US25515, filed on 2 Dec 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-67600P	19971205 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Russel, Jeffrey E.	
LEGAL REPRESENTATIVE:	Stewart, Mark J., Cox, Gregory A.	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	490	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 12 USPATFULL on STN

TI GLUCAGON-LIKE PEPTIDE-1 CRYSTALS

AB The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating diabetes, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:134217 USPATFULL  
TITLE: GLUCAGON-LIKE PEPTIDE-1 CRYSTALS  
INVENTOR(S): HERMELING, RONALD NORBERT, INDIANAPOLIS, IN, United States  
HOFFMANN, JAMES ARTHUR, GREENWOOD, IN, United States  
NARASIMHAN, CHAKAVARTHY, CARMEL, IN, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001014666	A1	20010816
	US 6380357	B2	20020430
APPLICATION INFO.:	US 1998-209799	A1	19981211 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ROBERT A CONRAD, ELI LILLY AND COMPANY, PATENT DIVISION/RSM, LILLY CORPORATE CENTER, INDIANAPOLIS, IN, 46285		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1106		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L11 ANSWER 11 OF 12 USPATFULL on STN

TI DERIVATIVES OF GLP-1 ANALOGS

AB The present invention relates to a pharmaceutical composition comprising  
a GLP-1 derivative having a lipophilic substituent; and a surfactant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:123563 USPATFULL  
TITLE: DERIVATIVES OF GLP-1 ANALOGS  
INVENTOR(S): KNUDSEN, LISELOTTE BJERRE, VALBY, Denmark  
HUUSFELDT, PER OLAF, KOBENHAVN K, Denmark  
NIELSEN, PER FRANKLIN, VARLOSE, Denmark  
KAARSHOLM, NIELS C., VANLOSE, Denmark  
OLSEN, HELLE BIRK, ALLEROD, Denmark  
BJORN, SOREN ERIK, LYNGBY, Denmark  
PEDERSEN, FREDDY ZIMMERDAHL, VARLOSE, Denmark  
MADSEN, KJELD, VARLOSE, Denmark

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001011071	A1	20010802
	US 6458924	B2	20021001
APPLICATION INFO.:	US 1999-398111	A1	19990916 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-265141, filed on 8 Mar 1999, PENDING Continuation-in-part of Ser. No. US 1999-258750, filed on 26 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-38432, filed on 11 Mar 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-918810, filed on 26 Aug 1997, ABANDONED A 371 of International Ser. No. WO 1997-DK340, filed on 22 Aug 1997, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1996-931	19960830
	DK 1996-1259	19961108
	DK 1996-1470	19961220
	DK 1998-263	19980227
	DK 1998-264	19980227
	DK 1998-268	19980227
	EP 1998-610006	19980313
	DK 1998-507	19980408
	DK 1998-272	19980227
	DK 1998-274	19980227
	DK 1998-508	19980408
	DK 1998-509	19980408
	US 1997-35904P	19970124 (60)
	US 1997-36226P	19970125 (60)
	US 1997-36255P	19970124 (60)
	US 1998-78422P	19980318 (60)

US 1998-82478P 19980421 (60)  
 US 1998-82479P 19980421 (60)  
 US 1998-82480P 19980421 (60)  
 US 1998-82802P 19980423 (60)  
 US 1998-84357P 19980505 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: STEVE T ZELSON, NOVO NORDISK OF NORTH AMERICA INC, 405  
 LEXINGTON AVENUE, SUITE 6400, NEW YORK, NY, 101746401  
 NUMBER OF CLAIMS: 238  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 1 Drawing Page(s)  
 LINE COUNT: 15340  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 12 USPATFULL on STN

TI Derivatives of GLP-1 analogs  
 AB The present invention relates to GLP-1 derivatives having a lipophilic  
 substituent, pharmaceutical compositions comprising same, and methods of  
 making an using same. The GLP-1 derivatives of the present invention  
 have a protracted profile of action.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:121450 USPATFULL  
 TITLE: Derivatives of GLP-1 analogs  
 INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, Denmark  
 Huusfeldt, Per Olaf, K.o slashed.benhavn K, Denmark  
 Nielsen, Per Franklin, V.ae butted.rl.o slashed.se,  
 Denmark  
 Kaarsholm, Niels C., Vanl.o slashed.se, Denmark  
 Olsen, Helle Birk, Aller.o slashed.d, Denmark  
 Bj.o slashed.rn, S.o slashed.ren Erik, Lyngby, Denmark  
 Pedersen, Freddy Zimmerdahl, V.ae butted.rl.o  
 slashed.se, Denmark  
 Madsen, Kjeld, V.ae butted.rl.o slashed.se, Denmark  
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S.  
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6268343	B1	20010731
APPLICATION INFO.:	US 1999-258750		19990226 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-38432, filed on 11 Mar 1998, now abandoned Continuation-in-part of Ser. No. US 1997-918810, filed on 26 Aug 1997, now abandoned Continuation-in-part of Ser. No. WO 1997-DK340, filed on 22 Aug 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1996-931	19960830
	DK 1996-1259	19961108
	DK 1996-1470	19961220
	DK 1998-263	19980227
	DK 1998-264	19980227
	DK 1998-268	19980227
	DK 1998-272	19980227
	DK 1998-274	19980227
	DK 1998-508	19980408
	DK 1998-509	19980408
	US 1997-35904P	19970124 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Borin, Michael

LEGAL REPRESENTATIVE: Zelson, Esq., Steve T., Lambiris, Esq., Elias J.  
NUMBER OF CLAIMS: 40  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 1 Drawing Page(s)  
LINE COUNT: 14165  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 17:28:33 ON 30 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT  
17:28:55 ON 30 JAN 2004

L1 7447 S GLP-1  
L2 514 S L1 AND ANALOG  
L3 61 S L2 AND (7-34)  
L4 1 S L3 AND TONICITY MODIFIER  
L5 61 S L3 AND SOLUTION  
L6 52 S L5 AND (7-35)  
L7 48 S L6 AND (7-37)  
L8 48 S L7 AND (7-36)  
L9 48 S L8 AND PH  
L10 4 S L8 AND BASIC PH  
L11 12 S L9 AND PRESERVATIVE

=> s l9 and TRIS

L12 31 L9 AND TRIS

=> s l12 and BRIJ-35

L13 2 L12 AND BRIJ-35

=> d l13 ti abs ibib tot

L13 ANSWER 1 OF 2 USPATFULL on STN

TI Derivatives of GLP-1 analogs

AB The present invention relates to a pharmaceutical composition comprising  
a GLP-1 derivative having a lipophilic substituent; and a surfactant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:283328 USPATFULL

TITLE: Derivatives of GLP-1 analogs

INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, DENMARK

Huusfeldt, Per Olaf, Kobenhavn K, DENMARK

Nielsen, Per Franklin, Vaerloose, DENMARK

Kaarsholm, Niels C., Vanlose, DENMARK

Olsen, Helle Birk, Allerod, DENMARK

Bjorn, Soren Erik, Lyngby, DENMARK

Pedersen, Freddy Zimmerdahl, Vaerloose, DENMARK

Madsen, Kjeld, Vaerloose, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199672	A1	20031023
APPLICATION INFO.:	US 2002-285079	A1	20020819 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-398111, filed on 16 Sep 1999, GRANTED, Pat. No. US 6458924		
	Continuation-in-part of Ser. No. US 1999-265141, filed on 8 Mar 1999, GRANTED, Pat. No. US 6384016		
	Continuation-in-part of Ser. No. US 1999-258750, filed on 26 Feb 1999, GRANTED, Pat. No. US 6268343		
	Continuation-in-part of Ser. No. US 1998-38432, filed on 11 Mar 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-918810, filed on 26 Aug 1997, ABANDONED		

Continuation-in-part of Ser. No. WO 1997-DK340, filed  
on 22 Aug 1997, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1996-931	19960830
	DK 1996-1259	19961108
	DK 1996-1470	19961220
	DK 1998-263	19980227
	DK 1998-264	19980227
	DK 1998-268	19980227
	EP 1998-610006	19980313
	DK 1998-507	19980408
	DK 1998-272	19980227
	DK 1998-274	19980227
	DK 1998-508	19980408
	DK 1998-509	19980408
	US 1997-35904P	19970124 (60)
	US 1997-36226P	19970125 (60)
	US 1997-36255P	19970124 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Reza Green, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6401	
NUMBER OF CLAIMS:	238	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	19138	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L13 ANSWER 2 OF 2 USPATFULL on STN

TI DERIVATIVES OF GLP-1 ANALOGS

AB The present invention relates to a pharmaceutical composition comprising  
a GLP-1 derivative having a lipophilic substituent; and a surfactant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:123563 USPATFULL  
TITLE: DERIVATIVES OF GLP-1 ANALOGS  
INVENTOR(S): KNUDSEN, LISELOTTE BJERRE, VALBY, Denmark  
HUUSFELDT, PER OLAF, KOBENHAVN K, Denmark  
NIELSEN, PER FRANKLIN, VARLOSE, Denmark  
KAARSHOLM, NIELS C., VANLOSE, Denmark  
OLSEN, HELLE BIRK, ALLEROD, Denmark  
BJORN, SOREN ERIK, LYNGBY, Denmark  
PEDERSEN, FREDDY ZIMMERDAHL, VARLOSE, Denmark  
MADSEN, KJELD, VARLOSE, Denmark

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001011071	A1	20010802
	US 6458924	B2	20021001
APPLICATION INFO.:	US 1999-398111	A1	19990916 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-265141, filed on 8 Mar 1999, PENDING Continuation-in-part of Ser. No. US 1999-258750, filed on 26 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-38432, filed on 11 Mar 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-918810, filed on 26 Aug 1997, ABANDONED A 371 of International Ser. No. WO 1997-DK340, filed on 22 Aug 1997, UNKNOWN		

NUMBER	DATE
-----	

PRIORITY INFORMATION: DK 1996-931 19960830  
 DK 1996-1259 19961108  
 DK 1996-1470 19961220  
 DK 1998-263 19980227  
 DK 1998-264 19980227  
 DK 1998-268 19980227  
 EP 1998-610006 19980313  
 DK 1998-507 19980408  
 DK 1998-272 19980227  
 DK 1998-274 19980227  
 DK 1998-508 19980408  
 DK 1998-509 19980408  
 US 1997-35904P 19970124 (60)  
 US 1997-36226P 19970125 (60)  
 US 1997-36255P 19970124 (60)  
 US 1998-78422P 19980318 (60)  
 US 1998-82478P 19980421 (60)  
 US 1998-82479P 19980421 (60)  
 US 1998-82480P 19980421 (60)  
 US 1998-82802P 19980423 (60)  
 US 1998-84357P 19980505 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: STEVE T ZELSON, NOVO NORDISK OF NORTH AMERICA INC, 405  
 LEXINGTON AVENUE, SUITE 6400, NEW YORK, NY, 101746401  
 NUMBER OF CLAIMS: 238  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 1 Drawing Page(s)  
 LINE COUNT: 15340  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 17:28:33 ON 30 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT  
 17:28:55 ON 30 JAN 2004

L1 7447 S GLP-1  
 L2 514 S L1 AND ANALOG  
 L3 61 S L2 AND (7-34)  
 L4 1 S L3 AND TONICITY MODIFIER  
 L5 61 S L3 AND SOLUTION  
 L6 52 S L5 AND (7-35)  
 L7 48 S L6 AND (7-37)  
 L8 48 S L7 AND (7-36)  
 L9 48 S L8 AND PH  
 L10 4 S L8 AND BASIC PH  
 L11 12 S L9 AND PRESERVATIVE  
 L12 31 S L9 AND TRIS  
 L13 2 S L12 AND BRIJ-35

=> d l12 ti abs ibib 1-15

L12 ANSWER 1 OF 31 USPATFULL on STN  
 TI Novel glucagon antagonists/inverse agonists  
 AB Novel compounds that act to antagonize the action of the glucagon  
 peptide hormone on the glucagon receptor. More particularly, it relates  
 to glucagon antagonists or inverse agonists.

ACCESSION NUMBER: 2004:19485 USPATFULL  
 TITLE: Novel glucagon antagonists/inverse agonists  
 INVENTOR(S): Lau, Jesper, Farum, DENMARK  
 Christensen, Inge Thoger, Lyngby, DENMARK



Madsen, Peter, Bagsvaerd, DENMARK  
Bloch, Paw, Taastrup, DENMARK  
Behrens, Carsten, Kobenhavn, DENMARK  
Kodra, Janos Tibor, Kobenhavn, DENMARK  
Nielsen, Poul Enrico, Borup, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014789	A1	20040122
APPLICATION INFO.:	US 2003-448529	A1	20030530 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2001-1789	20011203
	DK 2002-1006	20020627
	DK 2002-1927	20021217
	US 2002-394145P	20020703 (60)
	US 2002-434255P	20021218 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk Pharmaceuticals, Inc.,  
100 College Road West, Princeton, NJ, 08540  
NUMBER OF CLAIMS: 36  
EXEMPLARY CLAIM: 1  
LINE COUNT: 4435

L12 ANSWER 2 OF 31 USPATFULL on STN

TI Modified transferrin fusion proteins  
AB Modified fusion proteins of transferrin and therapeutic proteins or  
peptides including soluble toxin receptors, with increased serum  
half-life or serum stability are disclosed. Preferred fusion proteins  
include those modified so that the transferrin moiety exhibits no or  
reduced glycosylation, binding to iron and/or binding to the transferrin  
receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:313593 USPATFULL  
TITLE: Modified transferrin fusion proteins  
INVENTOR(S): Prior, Christopher P., King of Prussia, PA, UNITED STATES  
Lai, Char-Huei, King of Prussia, PA, UNITED STATES  
Sadeghi, Homayoun, King of Prussia, PA, UNITED STATES  
Turner, Andrew, King of Prussia, PA, UNITED STATES  
PATENT ASSIGNEE(S): BIOREXIS PHARMACEUTICAL CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003221201	A1	20031127
APPLICATION INFO.:	US 2003-378094	A1	20030304 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-231494, filed on 30 Aug 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-315745P	20010830 (60)
	US 2001-334059P	20011130 (60)
	US 2002-406977P	20020830 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004	
NUMBER OF CLAIMS:	86	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	

LINE COUNT: 5075  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 31 USPATFULL on STN

TI Glucagon antagonists/inverse agonists

AB A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312745 USPATFULL

TITLE: Glucagon antagonists/inverse agonists

INVENTOR(S): Lau, Jesper, Farum, DENMARK  
Madsen, Peter, Bagsvaerd, DENMARK  
Sams, Christian, Frederiksberg, DENMARK  
Behrens, Carsten, Copenhagen N, DENMARK  
Vagner, Josef, Oro Valley, AZ, UNITED STATES  
Christensen, Inge Thoger, Lyngby, DENMARK  
Lundt, Behrend Frederik, Kokkedal, DENMARK  
Sidelmann, Ulla Grove, Vedbaek, DENMARK  
Thogersen, Henning, Farum, DENMARK  
Ling, Anthony L., San Diego, CA, UNITED STATES  
Plewe, Michael Bruno, San Diego, CA, UNITED STATES  
Truesdale, Larry Kenneth, San Diego, CA, UNITED STATES  
Jogensen, Anker Steen, Copenhagen, DENMARK  
Kodra, Janos Tibor, Copenhagen, DENMARK  
Shi, Shenghua, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003220350	A1	20031127
APPLICATION INFO.:	US 2002-233851	A1	20020830 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-572553, filed on 16 May 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1999-684	19990517
	DK 2000-478	20000321
	US 1999-134415P	19990517 (60)
	US 2000-191685P	20000323 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington, New York, NY, 10174-6400

NUMBER OF CLAIMS: 88

EXEMPLARY CLAIM: 1

LINE COUNT: 13924

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 4 OF 31 USPATFULL on STN

TI Derivatives of GLP-1 analogs

AB The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:283328 USPATFULL

TITLE: Derivatives of GLP-1 analogs

INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, DENMARK  
Huusfeldt, Per Olaf, Kobenhavn K, DENMARK  
Nielsen, Per Franklin, Vaerloose, DENMARK

Kaarsholm, Niels C., Vanlose, DENMARK  
Olsen, Helle Birk, Allerod, DENMARK  
Bjorn, Soren Erik, Lyngby, DENMARK  
Pedersen, Freddy Zimmerdahl, Vaerlose, DENMARK  
Madsen, Kjeld, Vaerlose, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199672	A1	20031023
APPLICATION INFO.:	US 2002-285079	A1	20020819 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-398111, filed on 16 Sep 1999, GRANTED, Pat. No. US 6458924		
	Continuation-in-part of Ser. No. US 1999-265141, filed on 8 Mar 1999, GRANTED, Pat. No. US 6384016		
	Continuation-in-part of Ser. No. US 1999-258750, filed on 26 Feb 1999, GRANTED, Pat. No. US 6268343		
	Continuation-in-part of Ser. No. US 1998-38432, filed on 11 Mar 1998, ABANDONED		
	Continuation-in-part of Ser. No. US 1997-918810, filed on 26 Aug 1997, ABANDONED		
	Continuation-in-part of Ser. No. WO 1997-DK340, filed on 22 Aug 1997, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1996-931	19960830
	DK 1996-1259	19961108
	DK 1996-1470	19961220
	DK 1998-263	19980227
	DK 1998-264	19980227
	DK 1998-268	19980227
	EP 1998-610006	19980313
	DK 1998-507	19980408
	DK 1998-272	19980227
	DK 1998-274	19980227
	DK 1998-508	19980408
	DK 1998-509	19980408
	US 1997-35904P	19970124 (60)
	US 1997-36226P	19970125 (60)
	US 1997-36255P	19970124 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Reza Green, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6401	
NUMBER OF CLAIMS:	238	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	19138	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L12 ANSWER 5 OF 31 USPATFULL on STN

TI Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins

AB The present invention provides a means for increasing the serum half-life of a selected biologically active agent by utilizing transthyretin (TTR) as a fusion partner with a biologically active agent. Specifically, the present invention provides substantially homogenous preparations of TTR (or a TTR variant)-biologically active agent fusions and PEG-TTR (PEG-TTR variant)-biologically active agent fusions. As compared to the biologically active agent alone, the TTR-biologically active agent fusion and/or PEG-TTR-biologically active agent fusion has substantially increased serum half-life.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:277127 USPATFULL  
 TITLE: Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins  
 INVENTOR(S): Walker, Kenneth, Newbury Park, CA, UNITED STATES  
 Xiong, Fei, Thousand Oaks, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003195154	A1	20031016
APPLICATION INFO.:	US 2003-407078	A1	20030403 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-117109, filed on 4 Apr 2002, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	AMGEN INCORPORATED, MAIL STOP 27-4-A, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799		
NUMBER OF CLAIMS:	37		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Page(s)		
LINE COUNT:	3042		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L12 ANSWER 6 OF 31 USPATFULL on STN  
 TI Crystallisation of a GLP-1 analogue  
 AB Crystals of glucagon-like peptide-1 (GLP-1) and GLP-1 analogues, and processes for preparation of crystals of GLP-1 and GLP-1 analogues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2003:265841 USPATFULL  
 TITLE: Crystallisation of a GLP-1 analogue  
 INVENTOR(S): Arentsen, Anne Charlotte, Holte, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003186858	A1	20031002
APPLICATION INFO.:	US 2001-769692	A1	20010125 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	NL 2000-156	20000131
	US 2000-183300P	20000217 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6400	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1159	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L12 ANSWER 7 OF 31 USPATFULL on STN  
 TI C-aryl glucoside SGLT2 inhibitors and method  
 AB A method is provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of a compound of the formula ##STR1##

alone or in combination with one or more other antidiabetic agent(s) or other therapeutic agent(s).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:166532 USPATFULL  
TITLE: C-aryl glucoside SGLT2 inhibitors and method  
INVENTOR(S): Washburn, William N., Titusville, NJ, UNITED STATES  
Ellsworth, Bruce, Princeton, NJ, UNITED STATES  
Meng, Wei, Pennington, NJ, UNITED STATES  
Wu, Gang, Princeton, NJ, UNITED STATES  
Sher, Philip M., Plainsboro, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003114390	A1	20030619
APPLICATION INFO.:	US 2002-264410	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-805341, filed on 13 Mar 2001, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2410		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 8 OF 31 USPATFULL on STN

TI Heterocyclic compounds that are inhibitors of the enzyme DPP-IV  
AB The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV of formula I, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins that are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:153409 USPATFULL  
TITLE: Heterocyclic compounds that are inhibitors of the enzyme DPP-IV  
INVENTOR(S): Kanstrup, Anders Bendtz, Espergaerde, DENMARK  
Sams, Christian Klarner, Frederiksberg C, DENMARK  
Lundbeck, Jane Marie, Glostrup, DENMARK  
Christiansen, Lise Brown, Lyngby, DENMARK  
Kristiansen, Marit, Soborg, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003105077	A1	20030605
APPLICATION INFO.:	US 2002-186498	A1	20020628 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2001-1049	20010703
	DK 2002-180	20020206
	US 2001-309621P	20010802 (60)
	US 2002-356631P	20020208 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Reza Green, Esq.,, Novo Nordisk of North America, Inc.,, Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6401	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2972	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 31 USPATFULL on STN

TI Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:141004 USPATFULL

TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES  
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES  
Jeon, Yoon, Belle Mead, NJ, UNITED STATES  
Chen, Sean, Princeton, NJ, UNITED STATES  
Zhang, Hao, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003096846	A1	20030522
	US 6653314	B2	20031125
APPLICATION INFO.:	US 2002-80981	A1	20020222 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-812960, filed on 20 Mar 2001, GRANTED, Pat. No. US 6414002		
	Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-155400P	19990922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5718	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 10 OF 31 USPATFULL on STN

TI Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:127720 USPATFULL

TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES  
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES  
Jeon, Yoon, Belle Mead, NJ, UNITED STATES  
Chen, Sean, Princeton, NJ, UNITED STATES  
Zhang, Hao, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003087935	A1	20030508

APPLICATION INFO.: US 2002-81075 A1 20020222 (10)  
RELATED APPLN. INFO.: Division of Ser. No. US 2001-812960, filed on 20 Mar  
2001, PENDING Continuation-in-part of Ser. No. US  
2000-664598, filed on 18 Sep 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-155400P	19990922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Stephen B. Davis, Bristol-Myers Squibb Company, Patent Department, P.O. Box 4000, Princeton, NJ, 08543-4000	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5712	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 11 OF 31 USPATFULL on STN  
TI Indole carboxylic acids as thyroid receptor ligands  
AB A compound of the formula ##STR1##

wherein W, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6,  
R.sup.7, R.sup.8 and R.sup.13 are as defined herein, useful in the  
treatment of obesity, overweight condition, hyperlipidemia, glaucoma,  
cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism,  
thyroid cancer and related disorders and diseases such as diabetes  
mellitus, atherosclerosis, hypertension, coronary heart disease,  
congestive heart failure, hypercholesteremia, depression, osteoporosis  
and hair loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:113548 USPATFULL  
TITLE: Indole carboxylic acids as thyroid receptor ligands  
INVENTOR(S): Aspnes, Gary E., Rockville, RI, UNITED STATES  
Chiang, Yuan-Ching P., East Lyme, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003078289	A1	20030424
APPLICATION INFO.:	US 2002-255180	A1	20020924 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-325385P	20010926 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3688	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 12 OF 31 USPATFULL on STN  
TI Combination of FBPase inhibitors and antidiabetic agents useful for the  
treatment of diabetes  
AB A combination therapy of at least one FBPase inhibitor and at least one  
other antidiabetic agent is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:106816 USPATFULL  
TITLE: Combination of FBPase inhibitors and antidiabetic  
agents useful for the treatment of diabetes  
INVENTOR(S): van Poelje, Paul D., La Jolla, CA, UNITED STATES

Erion, Mark D., Del Mar, CA, UNITED STATES  
Fujiwara, Toshihiko, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073728	A1	20030417
APPLICATION INFO.:	US 2001-900364	A1	20010705 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-216531P	20000706 (60)
	US 2000-215126P	20000629 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BROBECK, PHLEGER & HARRISON LLP, 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130	
NUMBER OF CLAIMS:	114	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	12671	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 13 OF 31 USPATFULL on STN

TI Substituted acid derivatives useful as antidiabetic and antiobesity  
agents and method

AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and  
R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n  
are as defined herein, which compounds are useful as antidiabetic,  
hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:100164 USPATFULL

TITLE: Substituted acid derivatives useful as antidiabetic and  
antiobesity agents and method

INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES  
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES  
Jeon, Yoon, Belle Mead, NJ, UNITED STATES  
Chen, Sean, Princeton, NJ, UNITED STATES  
Zhang, Hao, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069275	A1	20030410
APPLICATION INFO.:	US 2002-80965	A1	20020222 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-812960, filed on 20 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-155400P	19990922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5710	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 14 OF 31 USPATFULL on STN

TI Protein formulations



AB The present invention discloses a stable, soluble formulation comprising a medically useful peptide or protein, a hydrophobic preservative, and nicotinamide. Said storage-stable, soluble formulation is useful as a multi-use pharmaceutical product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:100072 USPATFULL  
TITLE: Protein formulations  
INVENTOR(S): Rinella, Vincent Joseph, JR., Brownsburg, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069182	A1	20030410
	US 6573237	B2	20030603
APPLICATION INFO.:	US 2002-170301	A1	20020612 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-787500, filed on 16 Mar 2001, GRANTED, Pat. No. US 6440930		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	700		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 15 OF 31 USPATFULL on STN

TI Glucagon-like peptide-1 crystals

AB The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating diabetes, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:65340 USPATFULL  
TITLE: Glucagon-like peptide-1 crystals  
INVENTOR(S): Hermeling, Ronald Norbert, Indianapolis, IN, UNITED STATES  
Hoffmann, James Arthur, Greenwood, IN, UNITED STATES  
Narasimhan, Chakravarthy, Carmel, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003045464	A1	20030306
	US 6555521	B2	20030429
APPLICATION INFO.:	US 2001-997792	A1	20011130 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-209799, filed on 11 Dec 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69728P	19971216 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, LILLY CORPORATE CENTER, DROP CODE 1104, INDIANAPOLIS, IN, 46285	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1128	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

## Refine Search

### Search Results -

Terms	Documents
6358924.pn.	1

Database:

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

Search:

L4

Refine Search

Recall Text

Clear

Interrupt

### Search History

DATE: Friday, January 30, 2004   [Printable Copy](#)   [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set

*DB=USPT; PLUR=YES; OP=OR*

<u>L4</u>	6358924.pn.	1	<u>L4</u>
<u>L3</u>	6573237.pn.	1	<u>L3</u>
<u>L2</u>	6268343.pn.	1	<u>L2</u>
<u>L1</u>	6458924.pn.	1	<u>L1</u>

END OF SEARCH HISTORY